መነሻ › አኩት ማይሎይድ ሊውኬሚያ › ኮነቲከት
በኮነቲከት ለአኩት ማይሎይድ ሊውኬሚያ የሚደረጉ ክሊኒካዊ ጥናቶች
ለአኩት ማይሎይድ ሊውኬሚያ የሚደረጉ 17 ጥናቶች በኮነቲከት ባሉ ቦታዎች ተሳታፊዎችን እየፈለጉ ነው።
በኮነቲከት ውስጥ ያሉ ከተሞች
Official study text (English)
Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes
- Yale University, New Haven
ተሳታዮችን በመፈለግ ላይደረጃ 1
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ1 ኦክቶ 2026 · NCT06484062Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
- Yale University, New Haven
ተሳታዮችን በመፈለግ ላይደረጃ 2
እድሜ ከ18 እስከ 59 · ሁሉም ጾታዎች · የተሻሻለው በ28 ሴፕቴ 2026 · NCT05554393MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
- Yale University, New Haven
- Veterans Affairs Connecticut Healthcare System-West Haven Campus, West Haven
ተሳታዮችን በመፈለግ ላይደረጃ 2
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ25 ሴፕቴ 2026 · NCT05564390Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
- Yale University, New Haven
- Veterans Affairs Connecticut Healthcare System-West Haven Campus, West Haven
ተሳታዮችን በመፈለግ ላይደረጃ 2
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ22 ሴፕቴ 2026 · NCT06317649Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
- Yale University, New Haven
ተሳታዮችን በመፈለግ ላይደረጃ 2
እድሜ ከ18 እስከ 59 · ሁሉም ጾታዎች · የተሻሻለው በ22 ሴፕቴ 2026 · NCT05554406A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
- Connecticut Children's Medical Center, Hartford
- Yale University, New Haven
ተሳታዮችን በመፈለግ ላይደረጃ 3
6 Months – 21 Years · ሁሉም ጾታዎች · የተሻሻለው በ17 ሴፕቴ 2026 · NCT04293562The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- Connecticut Children's Medical Center, Hartford
- Yale University, New Haven
ተሳታዮችን በመፈለግ ላይደረጃ 1/2
እስከ እድሜ 22 · ሁሉም ጾታዎች · የተሻሻለው በ25 ኦገስ 2026 · NCT04726241Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
- Yale University, New Haven
ተሳታዮችን በመፈለግ ላይደረጃ 3
29 Days – 21 Years · ሁሉም ጾታዎች · የተሻሻለው በ24 ኦገስ 2026 · NCT05183035Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
- Hartford HealthCare Cancer Institute, Hartford
- Yale University School of Medicine, New Haven
ተሳታዮችን በመፈለግ ላይደረጃ 3
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ20 ኦገስ 2026 · NCT07007312Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- Smilow Cancer Hospital at Yale New Haven, New Haven
ተሳታዮችን በመፈለግ ላይደረጃ 1
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ20 ኦገስ 2026 · NCT06001788ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies
- Yale University, Yale Cancer Center, New Haven
ተሳታዮችን በመፈለግ ላይደረጃ 1
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ18 ኦገስ 2026 · NCT06656494A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- Yale New Haven Hospital, New Haven
ተሳታዮችን በመፈለግ ላይየመመልከት ጥናት
ለሁሉም እድሜ · ሁሉም ጾታዎች · የተሻሻለው በ6 ጁላይ 2026 · NCT01351545BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia
- Yale New Haven Hospital, New Haven
ተሳታዮችን በመፈለግ ላይደረጃ 1
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ15 ጁን 2026 · NCT05768932A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
- Yale University, New Haven
ተሳታዮችን በመፈለግ ላይደረጃ 2/3
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ30 ኤፕሪ 2026 · NCT04256317Revumenib in Combination With 7+3 + Midostaurin in AML
- Yale Cancer Center, New Haven
ተሳታዮችን በመፈለግ ላይደረጃ 1
እድሜ ከ18 እስከ 75 · ሁሉም ጾታዎች · የተሻሻለው በ25 ማርች 2026 · NCT06313437A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
- Yale Cancer Center and Smilow Cancer Hospital, New Haven
ተሳታዮችን በመፈለግ ላይደረጃ 1
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ13 ማርች 2026 · NCT05735184Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia
- Yale University, New Haven
ተሳታዮችን በመፈለግ ላይደረጃ 1/2
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ26 ኦገስ 2025 · NCT03850574ከ ClinicalTrials.gov የተገኘ መረጃ፣ በ5 ኦክቶ 2026 የተሰብሰቡ። እያንዳንዱ ጥናት የራሱን ቅድመ ሁኔታ ይወስናል፤ የጥናት ቡድኑ ማን መሳተፍ እንደሚችል ይወስናል።